一例同时患前列腺癌与肾细胞癌患者的177镥-PSMA治疗
77岁转移性前列腺癌男性,抗雄激素治疗后骨痛严重、PSA升高,68Ga-PSMA PET/CT显示广泛PSMA阳性骨转移及偶发PSMA高摄取肾肿块,后者确诊为肾细胞癌。患者接受四周期177Lu-PSMA-617,骨痛完全缓解、骨转移明显改善、PSA下降,但肾肿块未见变化;177Lu-PSMA-617对肾细胞癌未见显著治疗效应。
要点
- 77岁转移性前列腺癌患者接受四周期177Lu-PSMA-617后骨痛完全缓解、骨转移明显改善、PSA下降。
- 68Ga-PSMA PET/CT偶发PSMA高摄取肾肿块,后确诊为肾细胞癌。
- 177Lu-PSMA-617对肾细胞癌未见显著治疗效应,肾肿块未见变化。
核心结论
- 177Lu-PSMA-617对转移性前列腺癌产生骨痛完全缓解、骨转移明显改善和PSA下降,但对并发的肾细胞癌未见显著治疗效应。
- 177Lu-PSMA治疗在非前列腺恶性肿瘤中的疗效仍在研究中。
研究设计与样本
- 本文为单例病例报告,患者为77岁转移性前列腺癌男性。
主要发现
- 患者抗雄激素治疗后仍骨痛严重、PSA升高,68Ga-PSMA PET/CT显示广泛PSMA阳性骨转移及偶发PSMA高摄取肾肿块。
- 肾肿块 later 确诊为肾细胞癌。
- 患者接受四周期177Lu-PSMA-617后骨痛完全缓解、骨转移明显改善、PSA下降,肾肿块未见变化。
- 177Lu-PSMA-617对肾细胞癌未见显著治疗效应。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 77-year-old man with metastatic prostate cancer presented with debilitating bone pain and rising PSA despite anti-androgen therapy. 68 Ga-PSMA PET/CT scan revealed widespread PSMA-positive bone metastases with an incidental PSMA-avid renal mass, later confirmed as renal cell carcinoma (RCC). The patient received four cycles of 177 Lu-PSMA-617, which resulted in complete pain resolution, marked improvement in bone metastases, and PSA reduction; while no change in the renal mass is noted. Despite the beneficial effects of 177 Lu-PSMA therapy in metastatic prostate cancer, its efficacy in nonprostatic malignancies is under investigation. In this case, 177 Lu-PSMA-617 did not show remarkable therapeutic efficiency in RCC.
引用
- Albooyeh H, Amini H, Arefnia M, et al. 177 Lutetium-PSMA Therapy in a Patient With Concurrent Prostate Cancer and Renal Cell Carcinoma. Clin Nucl Med. 2025. PMID: 40494366. doi:10.1097/RLU.0000000000005964
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。